To identify genes associated with tumor metastasis in hepatocellular carcinoma (HCC), gene expression profiles between a pair of primary HCC (H2-P) and their matched metastatic HCC (H2-M) were compared. Overexpression of clusterin (CLU) was found in H2-M cells. To determine the roles CLU played in HCC metastasis, CLU was transfected into H2-P cells. Overexpression of CLU in H2-P cells increased cell migration by twofold in vitro and formation of metastatic tumor nodules in liver by eightfold in vivo. To evaluate the correlation of CLU expression with HCC metastasis, the expression levels of CLU in HCCs were investigated using a tissue microarray (TMA) containing 104 pairs of primary HCCs and their matched metastases. The frequency of CLU overexpression increased significantly in metastatic HCCs (59.1%) compared with that in primary tumors (32.6%, Po0.001). To gain additional insight into the function of CLU, the expression profile of H2P-CLU was compared with vector-transfected H2-P cells by cDNA microarray. A total of 35 upregulated and 14 downregulated genes were detected in H2P-CLU. One of the upregulated genes known as YKL-40, which is implicated in matrix-remodeling and metastasis, was further studied using TMA. A significant correlation (Po0.001) between the expression levels of YKL-40 and CLU was observed, implying that the CLU-YKL-40 pathway may play an important role in HCC metastasis.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common and aggressive tumors. It is ranked as the fifth most frequent cancer, but the third leading cause of cancer death worldwide. Prognosis of HCC is extremely poor with a 5-year survival rate of less than 5% for late primary HCC (Block et al., 2003) . The poor prognosis of HCC patients is mainly attributed to the high rate of intrahepatic metastasis after treatment (Nagao et al., 1990) . Despite the advances in molecular technologies, which allow the identification of novel targets involved in HCC metastasis, the precise mechanisms involved remain elusive. Previously, in an attempt to identify metastasis-associated genes in HCC, a pair of primary HCC (H2-P) and metastatic HCC (H2-M) cell lines from the same patient were established (Hu et al., 2004a) . Gene expression profiles between H2-P and H2-M were compared by cDNA microarray, and the results revealed a significant overexpression of both clusterin mRNA and protein in H2-M cells (Hu et al., 2004b) .
Clusterin (CLU), a highly conserved glycoprotein, which enhances cell aggregation in vitro, was first isolated from the rat testis (Blaschuk et al., 1983) . A broad range of functions have been ascribed to CLU, including tissue remodeling, adhesion, apoptosis, cell proliferation, senescence, membrane recycling, lipid transportation, complement inhibition and sperm maturation (Trougakos and Gonos, 2002) . Interestingly, a growing body of evidence suggested a prominent role of CLU upregulation in tumor pathogenesis and progression. Upregulated expression of CLU has been reported in cancers of the breast (Redondo et al., 2000) , ovary (Xie et al., 2005) , colon (Chen et al., 2003) , prostate (Steinberg et al., 1997) , and kidney (Miyake et al., 2002) . Several studies have correlated overexpression of CLU with tumor metastasis. For instance, introduction of the clusterin gene into renal carcinoma cells resulted in enhanced formation of metastatic nodules in vivo (Miyake et al., 2002) . In addition, the expression level of clusterin was contrastive in breast cancer, where normal breast epithelial cells were always negative for CLU expression (Redondo et al., 2000) . A similar expression pattern was observed in our recent study on ovarian carcinoma (Xie et al., 2005) . In this report, the expression levels and effects of overexpression of CLU in primary HCC cells were investigated. Furthermore, the potential downstream targets of CLU were analysed using cDNA microarray technology.
Results

Introduction of CLU into H2-P cells increased cell migration and tumor metastasis
To examine the role of clusterin in HCC metastasis, a stable clone expressing high level of clusterin was selected (Figure 1a and b) . Cell migration assay was performed to compare the migration rate between H2P-CLU cells and empty vector-transfected H2-P (H2P-Vec) cells. Results showed that introduction of clusterin into H2-P significantly increased (Btwofold) cell migration rate (Figure 2) . The growth rate of H2P-CLU cells was also compared with H2P-Vec and no obvious difference was found between them ( Figure 1c) . To further study the correlation between CLU overexpression and HCC metastasis, H2P-CLU, H2P-Vec and the parental H2-P cells were injected into the tail veins of SCID mice. Injection of CLUoverexpressing cells (H2P-CLU) resulted in a more than eightfold increase in metastatic tumor nodule formation on the liver surface (Table 1; Figure 3b -d). Tumor nodules formed on the liver surface and within the liver were confirmed by pathological study. One example of tumor nodule formed within the liver of a SCID mouse injected with H2P-CLU cells is shown in Figure 3e . Metastatic situation in lungs was also macroscopically checked and no visible metastatic lesion was found.
Overexpression of CLU in metastatic HCC cases
To examine the expression level of CLU in HCC cases, two tissue microarray (TMA) blocks containing a total of 104 pairs of primary HCC with their matched metastases were used for IHC analysis. As the expression of cytoplasmic clusterin was negative or weakly positive in the majority of non-neoplastic liver cells (>90%), non-neoplastic liver tissues was defined as having a staining index of less than or equal to 3. Therefore, a staining index of 0-3 was taken as normal expression of clusterin, while a staining index of 4-9 was taken as overexpression of this protein. Using this designation we were able to evaluate CLU expression in 93 pairs of informative cases. IHC results showed that overexpression of CLU was significantly higher in metastatic HCCs (55/93 cases, 59.1%) than that in Figure 6c and e. Another interesting finding in the present study was that overexpression of cytoplasmic isoform of clusterin (cCLU) was found to be predominant in H2P-CLU and H2-M cells (Figure 4a-d) . Predominant of cCLU overexpression was also found in liver metastatic nodule formed in SCID mice (Figure 4e and f) and clinical metastatic HCC (Figure 6e ).
Analysis of H2P-CLU cells using cDNA microarray
To obtain further insight into the functions of CLU in HCC metastasis, expression profiles of H2P-CLU were compared with H2P-Vec using a cDNA microarray containing 9184 genes. A total of 35 upregulated and 14 downregulated genes were identified in H2P-CLU compared to those in H2P-Vec (Table 2 ). To validate the cDNA array results, 11 differentially expressed genes were selected and analysed by Northern blot hybridization. The results were consistent with the findings from cDNA array ( Figure 5 ). Interestingly, many differentially expressed genes were implicated in different aspects of tumor metastasis including cell migration and (YKL-40, IGFBP1, and SAA), invasion (APOE, MMP1, MMP7, and CTSS) and metastasis (ERBB3, COL1A1, CYR61, and CTGF). Among these genes, 
Discussion
To date, metastasis has remained one of the major challenges in the treatment of HCC (Tang et al., 2004) .
The metastatic process consists of a series of steps, which resulted in the movement of tumor cells from a primary tumor to a remote site (Chambers et al., 2002) . Deregulation of different cellular processes including migration, invasion, apoptosis, and angiogenesis are evident during the process of metastasis. Different approaches have been used to identify the target genes involved. Recently, by comparing a pair of cell lines constructed from a primary HCC case (H2-P) and its matched metastasis (H2-M) (Hu et al., 2004b) , we reported the overexpression of a 76-80 kDa isoform of CLU in H2-M cells. Clusterin is a versatile protein implicated in a broad range of functions. The functional relationship of CLU to apoptosis has been intensively studied. Highly controversial results suggested that CLU can be either apoptotic or antiapoptotic, depending on the cellular setting (Trougakos and Gonos, 2002) . Recently, Leskov et al. (2003) identified a nuclear form of clusterin (nCLU), which is able to induce apoptosis following exposure to ionizing radiation. Furthermore, Pucci et al. (2004) demonstrated a difference in CLU isoform expression during colon tumorigenesis. Predominant expression of the 50-55 kDa nCLU, which induces apoptosis, was found in normal colonic mucosa, while overexpression of the cytoplasmic form (cCLU) occurs in highly aggressive tumor and metastatic nodules. This isoform shift in CLU expression provides a possible explanation for the divided view on clusterin's function, and is in accordance with our observation that overexpression of cCLU predominates in H2P-Clu and H2-M cells (Figure 4a-d) , liver metastatic nodules formed on SCID mice (Figure 4e and f) and clinical metastatic HCC (Figure 6e ). In our recent study, upregulated expression of cCLU was also detected in invasive ovarian carcinomas (Xie et al., 2005) , further reiterating the importance of cytoplasmic clusterin expression in tumor progression. Apart from modulating apoptosis, CLU has been implicated in tissue remodeling processes. For instance, CLU was dramatically induced in vascular smooth muscle cells (VSMC) after vascular injury (Miyata et al., 2001) . Also, expression of clusterin in VSMC induced migration and nodule formation (Millis et al., 2001) . Our data in this study support this view that overexpression of cCLU in HCC cells significantly enhances cell migration and plays an important role in HCC metastasis. In fact, modulation of cell invasion and migration properties is a complex but critical step in the metastatic process, involving many different escape mechanisms (Friedl and Wolf, 2003) .
Although the precise function of CLU remains debatable, a growing body of evidence suggests that overexpression of this protein is implicated in tumorigenesis and metastasis (Steinberg et al., 1997; Redondo et al., 2000; Miyake et al., 2002; Chen et al., 2003; Xie et al., 2005) . In a recent study, using a mouse model with Pten conditional prostate deletion, Wang et al. (2003) reported that increased CLU expression was found in mutant mouse prostate. These results reiterate the multiple aspects of CLU involvement in cancer metastasis. In this study, we also demonstrated that overexpression of CLU significantly increased cell migration in vitro and formation of liver metastases in vivo. Interestingly, no visible metastatic lesion was observed in lungs of the tested mice. Actually, our previous study showed that H2-P and H2-M can only form tumors in liver in both nude mice and SCID mice (data not shown). This might be related with the suitable cell growth environment provided by liver. Also, this is in accordance with the notion that liver is the primary organ of HCC metastasis where HCC frequently disseminates through the portal vasculature (Mitsunobu et al., 1996) .
To gain further insight into the downstream molecular events involving CLU and HCC development, we compared expression profiles between H2P-CLU and H2P-Vec using the cDNA microarray approach. Out of 9184 genes, 49 were differentially expressed by twofold or more. These included 35 upregulated and 14 downregulated genes identified in H2P-CLU cells (Table 2) , as validated by Northern analysis (Figure 5 ). Interestingly, a large proportion of them are implicated in tumor progression (YKL-40, SAA, ERBB3, IGFBP1, APOE, and KRT20), and cell migration and invasion (YKL-40, SAA, DSPG3, IGFBP1, CTSS, APOE, MMP1, and MMP7). In addition, many genes are closely related to liver functions (YKL-40, SAA, ALB, GST, APOCI, APOE, and IGFBP1).
In attempt to identify molecular target(s) related to clusterin function, genes deregulated in H2P-CLU cells were also compared with the signature genes of parental H2-M cells (Hu et al., 2004b) . Among 49 differentially expressed genes in H2P-CLU cells, four upregulated ones (TSPY, ALB, YKL40 and ORM1) were found overexpressed in H2-M cells. One of the most interesting targets is YKL-40/chitinase 3-like 1 (CHI3L1). YKL-40 is located on human chromosome 1q31-q32, a region frequently amplified in HCC (Lau and Guan, 2005) . It was first isolated from porcine VSMC, which is highly induced during nodule formation, but the precise function of this gene is presently unknown. High serum expression of YKL-40 has been associated with poor prognosis in colorectal cancer (Cintin et al., 1999) , glioblastoma multiforme (Tanwar et al., 2002) , breast cancer (Johansen et al., 1995) , ovarian cancer (Dehn et al., 2003) , and lung cancer (Johansen et al., 2004) . Consistent with the function of CLU, overexpression of YKL-40 has been implicated in increased migration and tissue remodeling. For example, YKL-40 potently induces migration of endothelial cells (Malinda et al., Figure 6 Examples of CLU and YKL-40 expressions in primary and metastatic HCC tissues as detected by IHC. Normal expression of CLU (a) and YKL-40 (b) were observed in non-neoplastic adjacent liver tissues. Overexpression of CLU (c, staining index ¼ 6) and YKL-40 (d, staining index ¼ 6) were detected in the primary HCC, and increased expression levels of CLU (e, staining index ¼ 9) and YKL-40 (f, staining index ¼ 9) were observed in metastatic lesions. All non-neoplastic adjacent liver tissues, primary HCC tissues, and metastatic lesions shown were obtained from the same patient ( Â 100 magnification). 1999) and VSMC (Nishikawa and Millis, 2003) . In this study, expression profiling revealed a dramatic overexpression of YKL-40 in H2P-CLU cells. To examine the correlation between CLU and YKL-40 expression, TMA containing 43 cases were used. A significant correlation (Po0.001) between the expression levels of YKL-40 and CLU was observed, implying that the CLU-YKL-40 pathway may play an important role in HCC metastasis. Better understanding of the physiological and pathophysiological functions of CLU and YKL-40 may lead to more effective management of HCC metastasis, via precise prognostication and treatment targeted at these or related molecules.
Materials and methods
Cell lines and transfection of CLU into H2-P A primary HCC cell line (H2-P) and its matched metastatic cell line (H2-M) were established in our laboratory (Hu et al., 2004a) . The full coding region of CLU was cloned into expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA, USA) and transfected into H2-P cells using lipofectamine (Life Technologies, Inc., Gaithersburg, MD, USA) according to the manufacturer's instructions. Stable transfectants were selected using Geneticin (Life Technologies, Inc.) at a concentration of 300 mg/ml. Expression levels of CLU were confirmed by Northern and Western blot analyses. Mock transfection of pcDNA3.1 alone was performed in parallel as negative control.
Northern and Western blot analyses
For Northern blot analysis, 10 mg of total cellular RNA was size fractionated on 1% agarose/2.2 M formaldehyde gel, transferred onto a nylon membrane, and hybridized with 32 P-labeled probes. For Western blotting, 30 mg of protein extract was resolved by 10% SDS-polyacrylamide gel electrophoresis and transferred onto a PVDF Hybond-P membrane (Amersham Pharmacia Biotechnology, Piscataway, NJ, USA) by electro-blotting. The protein blot was blocked in 2% blocking solution overnight and incubated with a 1:100-dilution monoclonal antibody against human clusterin (Clone 41D, Upstate biotechnology, Lake Placid, NY), followed by goat-anti-mouse secondary antibody. Immunoreactions were visualized with ECL plus (Amersham Pharmacia Biotechnology) reagents, according to the manufacturer's instruction.
Cell growth assay
Cell growth rate was determined by the XTT-based Cell Proliferation Kit II (Roche, Mannheim, Germany), according to the manufacturer's instructions. Briefly, cells were seeded onto 96-well plate at a density of 1.5 Â 10 4 cells/well and incubated for 0-6 days. For each assayed time point, 50 ml of freshly prepared XTT reagent was added per well and incubated for 4 h at 371C. Cell growth rate was measured by the absorbance of the formazan product at a wavelength of 492 nm. Each experiment was repeated at least three times.
Cell migration assay
The cell migration assay was performed in a polyethylene terephthalate (PET)-based migration chamber (Becton Dickinson Labware, Franklin Lakes, NJ, USA) with 8 mm porosity. Cells were serum starved for 24 h before the migration assays. A migration chamber was placed in each well of a 24-well plate with 500 ml of DMEM containing 10% FBS. For the upper side of the chamber, 10 000 cells were seeded in DMEM medium supplemented with 1% FBS. After incubation for 48 h at 371C, cells remaining on the upper surface of the chambers were removed by a cotton swab. To visualize migrated cells, the PET membrane was stained with 0.1% crystal violet for 10 min. All assays were performed in triplicate, and at least three independent experiments were performed.
Experimental metastasis assay
Female severe combined immunodeficient (SCID-Beige) mice aged between 6 and 8 weeks were used and each experimental group (H2-P, H2-P-Vec and H2P-CLU) consisted of four mice. Briefly, 1 Â 10 6 cells were injected intravenously through the tail vein into each SCID mouse. All mice were killed 6 weeks postinjection. The presence of tumor nodules was macroscopically determined and the number of tumor nodules formed on the liver surface was counted. We performed all animal procedures in full accordance with the Committee on the Use of Live Animals in Teaching and Research (CULATR)-approved protocol, using a minimal number of mice and killing them all at 6 weeks, to avoid excessive tumor burden.
cDNA microarray Production of cDNA microarrays with 9184 human cDNAs, sample labeling and hybridization were performed as described previously (Hu et al., 2004b) . Briefly, total RNA was extracted by Trizol reagent (Gibco BRL, Gaithersburg, MD, USA) and further purified using the RNeasy Kit (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's protocol. For RT labeling, 120 mg of total RNA from H2P-CLU and H2P-Vec was individually labeled with Cy3-dUTP or Cy5-dUTP (Perkin-Elmer Life Sciences, Boston, MA, USA) using the SuperScript II reverse transcription kit (Invitrogen, Carlsbad, CA, USA). Fluorescently labeled targets were combined and purified by Microcon YM-30 filters (Millipore, Bedford, MA, USA), followed by overnight hybridization at 651C.
Primary image and data analysis was performed using the GenePix Pro 4.0 software package (Axon Instruments, Forster City, CA, USA) The Cy5 to Cy3 ratio was determined for the individual gene along with various quality control parameters. Spots with small diameters (o120 mm), low signal strengths (o300 fluorescence intensity units) and low signal-to-noise ratio (o1.5) were discarded. For data reproducibility, dye reversal labeling was performed to minimize systematic bias and only high-quality data points were included. Elements with at least a twofold difference in expression level were defined as differentially expressed.
TMA construction
Two TMA blocks containing primary and matched metastatic HCCs were constructed. Block A contained 60 pairs of primary HCCs and their matched metastatic tumors from . TMA was constructed as described previously (Wang et al., 2002) . Multiple sections (5 mm thick) were cut from the two TMA blocks and mounted on microscope slides.
Immunohistochemistry (IHC)
IHC studies were performed using a standard streptavidinbiotin-peroxidase complex method (Xie et al., 2005) . In brief, TMA sections were deparaffinized and rehydrated. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 20 min. For antigen retrieval, TMA slides were microwave-treated in 10 mM citrate buffer (pH 6.0) for 5 min (for CLU) or 8 min (for YKL-40). Nonspecific binding was blocked with 10% normal rabbit serum for 10 min. The TMA slides were incubated with a 1:200 dilution of monoclonal against human clusterin (Clone 41D; Upstate Biotechnology) or a 1:100 dilution of anti-human YKL-40 monoclonal (Quidel, San Diego, CA, USA) for 60 min at 371C in a moist chamber. The slides were then sequentially incubated with biotinylated rabbit anti-mouse antibody at a concentration of 1:100 for 30 min at 371C, and subsequently reacted with streptavidin-peroxdase conjugate for 30 min at 371C. 3 0 -3 0 diaminobenzidine was used as the chromogen substrate. Finally, all slides were counterstained for nuclei with Meyer's hematoxylin, dehydrated and mounted. To avoid false positives, negative controls were included in every test by replacing the primary antibody with mouse IgG. In addition, breast cancer cases with known positive immuno-staining were included as positive controls. As the IHC conditions for all tissues in the TMA sections were identical, a semiquantitative scoring system was used for IHC evaluation as described previously (Xie et al., 2005) . Both the staining intensity and the percentage of positively stained tumor cells were recorded. A staining index (values 0-9), obtained as the intensity of clusterin or YKL-40 positive staining (negative ¼ 0, weak ¼ 1, moderate ¼ 2, or strong ¼ 3) multiplied by the proportion of immuno-positive cells of interest (o10% ¼ 1, 10-50% ¼ 2, >50% ¼ 3), was calculated. Lost samples, unrepresentative samples, and samples with too few tumor cells (o100 cells) were classified as noninformative and excluded from data analysis.
Statistical analysis
Statistical analysis was performed with the SPSS software (SPSS Standard version 8.0). The statistical significance of the correlation between the expression of clusterin and YKL-40 was evaluated by Fisher's exact test with P-values of less than 0.05 considered significant. The associations between CLU expression and cell proliferation, cell migration and tumor formation in SCID mice were assessed by two-tailed unpaired Student's t-test with P-values of less than 0.05 designated as statistically significant.
